Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial Operations

   Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial
                                  Operations

PR Newswire

ATLANTA, Nov. 6, 2012

ATLANTA, Nov. 6, 2012 /PRNewswire/ --Arbor Pharmaceuticals, a specialty
pharmaceutical company based in Atlanta, GA, announced today that Thom Rowland
has joined the company as VP of Commercial Operations. Mr. Rowland is an
industry veteran who started his career starting as a sales representative for
UCB Pharmaceuticals. He later held various marketing positions with UCB prior
to taking the position of head of marketing for Scandipharm. He played a lead
role in turning the Scandipharm business around prior to its sale to Axcan
Pharmaceuticals. Thom then served as a VP of Sales and Marketing for several
business units at Solvay Pharmaceuticals where he was again instrumental in
turning around an underperforming area. Thom was one of the founders of
Ventrus Biosciences which completed a successful IPO in 2010. 

Ed Schutter, President and CEO of Arbor, commented, "We are pleased that Thom
has joined Arbor at this crucial time in our development as an organization.
As our business grows and we become more complex, we felt it was essential
that we have someone of Thom's level of experience on board. I'm confident
Thom will optimize our current business as well as our future product
launches."

Mr. Rowland added, "Arbor has achieved tremendous growth over its short
history and is well positioned for future growth. I am pleased to be joining
this highly productive organization at this exciting time and look forward to
leading the commercial team to continued success."

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty
pharmaceutical company currently focused on the cardiovascular, pediatric and
hospital markets. The company intends to become a leading specialty
pharmaceutical company by actively licensing, developing and commercializing
late-stage products for specialty focused conditions. Arbor currently markets
multiple NDA and ANDA approved products with several more in development.

For more information regarding Arbor Pharmaceuticals or any of its products,
visit www.arborpharma.com or send email inquiries to info@arborpharma.com.



SOURCE Arbor Pharmaceuticals, Inc.

Website: http://www.arborpharma.com
Contact: Jason McCarthy, +1-678-334-2423